Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Jul 1, 2019, 00:00
10.1016/j.jval.2019.05.002
https://www.valueinhealthjournal.com/article/S1098-3015(19)32180-1/fulltext
Title : Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32180-1&doi=10.1016/j.jval.2019.05.002
First page : 843
Section Title : CORRECTION
Open access? : No
Section Order : 843

Value in Health. 2019;22(4):408-415.

DOI of original article: https://doi.org/10.1016/j.jval.2018.11.014

In the introduction section of the article by Garrison et al, the percentages for the 4-year invasive disease-free survival rates for the pertuzumab arm and the control arm were inadvertently transposed. The corrected sentence below reflects the appropriate 4-year invasive disease-free survival values for each arm, as shown in Figure 1A of the pivotal trial publication by von Minckwitz et al:

The 4-year invasive disease-free survival (iDFS) was 92.3% in the pertuzumab arm and 90.6% in the control arm.

Categories :
  • Oncology
Tags :
Regions :
ViH Article Tags :